



**A Full-service Global CRO**

India | USA | Canada | UK | Poland

# Comprehensive End-to-End Services



# Awards & Accolades

**REGULATORY  
& COMPLIANCE  
EXCELLENCE**

CPHI Pharma  
Awards 2023



**INDUSTRY  
PARTNER  
OF THE YEAR**

Global Generics &  
Biosimilars Awards  
2023



# Global Presence



# Impeccable Regulatory Track Record

## Lambda



NGCMA - India



Austria



Belgium



Brazil



Canada



Czech Republic



France



Germany



Gulf Cooperation Council



Hungary



Ireland



Italy



Kazakhstan



Latvia



Malaysia



Netherlands



Poland



Portugal



Slovakia



Spain



Thailand



Turkey



NABL



CAP

## Novum





- Multicontinental presence
- End-to-end clinical research services
- Robust digital platforms across business verticals
- Hub & Spoke, flexible business models



- Global Revenues of USD 90 million in FY 23-24
- Growing at 29% CAGR YoY
- Best credit rating in the CRO industry



- Strong Leadership with 35+ years of experience
- Multicultural workforce
- 1200+ employees



- Impeccable regulatory track record
- Independent Quality Assurance
- Stringent GXP Compliance




# Early Development & Innovation

*Navigate the complex landscape of early-stage drug development*


# Global Bed Capacity & Volunteer Database

## 700+ Beds Globally




## Volunteer Database


### LAMBDA - AHMEDABAD



### LAMBDA - MEHSANA



### NOVUM - USA



## Extensive Capabilities

- ✓ Single / Multiple Ascending Dose (SAD/MAD)
- ✓ First-in-human (FIH)
- ✓ Biosimilars
- ✓ Drug-Drug Interaction
- ✓ Food-Drug Interaction
- ✓ Drug-Device Combinations
- ✓ PK-PD Proof-of-Concept
- ✓ Food effect studies
- ✓ Cardiac Safety studies
- ✓ Inhalation studies
- ✓ Dermatology Studies
- ✓ Human Factor Studies
- ✓ Self-administration Studies

A photograph of a hospital room with two beds, medical equipment, and large windows. The image is partially obscured by a large blue shape on the left and a large orange triangle on the right.

**CPUs in  
Ahmedabad (India)  
& Las Vegas (USA)**

## 7500+ Studies with diverse formulation experience



# PK/PD Studies

First in the Industry to Implement IRIS registration facility



Experience of conducting 7500+ PK/PD studies



24/7 Medical coverage



Advanced ICU facilities



Negative pressure inhalation chambers



Real-time data capture



Controlled substance studies



Safety & Bioanalytical lab with Sample Management System



Mixed population studies



# Nutraceuticals & Consumer Products Studies



**Over The Counter (OTC) Products**



**Hair Re-growth Products**




**Skin & Personal Hygiene products**



**De-Addiction Products**



**Multivitamins & Nutritional supplements**



**Fortified Food Products**

Edible Oil, Flours, Fruit Extracts, Milk products, Rice extracts


**132** Total Study experience


**9** Nutraceutical Products

**82** Oral Care Products

**41** Skin & Personal Hygiene Products


# Proteins and Peptides Experience





## Extensive Experience in conducting Controlled substance studies

- Qualified by FDA to conduct Schedule II - V products
- Vast experience with products requiring a DEA 222 form
- Extensive opioid experience for products that require the co-administration of naltrexone



## Vast Experience in conducting studies for NCEs

- Extensive experience in SAD/MAD studies.
- Experience Encompasses Small Molecules & Large Molecules for Pharma and Biotech Clients
- Scientific Expertise & Operational Expertise: Collaborative Environment (Partnership) for Successful Study Conduct:

# Pharmacodynamic Staff Training




- Adhesion Scoring
- C-SSRS
- Dermal Response Scoring
- Intense Blood Pressure Monitoring
- Intense ECG Measurements
- Standard 12-lead, Holter Monitors and Telemetry
- Ophthalmology Testing
- Skin Biopsies
- Symptom Score Questionnaires
- Taste / Palatability / Dose Acceptance
- Visual Analog Score



# Phase II-IV Clinical Trials

*Vast Therapeutic Expertise, Global Reach, and Seamless Execution*

# Experience the Lambda Advantage



# Late Phase Clinical Studies

	Therapeutic Areas	Studies	Patients
	Dermatology	105	41695
	Oncology	67	5128
	Neuropsychiatry	23	4332
	Pulmonology	19	17212
	Women's Health	15	5516
	Musculoskeletal	12	4721
	Gastroenterology	7	1861
	Infectious Diseases	7	2156
	Metabolic Disorders	6	660
	Ophthalmology	4	758
	Cardiology	2	224
	General Medicine	1	369



268

Multi-centric Studies

3000+

Sites

80000+

Patients Enrolled

Extensive Experience in

**Oncology & Dermatology**

Proven Expertise in

**Biosimilars**

# Patient-based PK Studies

Indications / Therapy	Studies	Patients
Schizophrenia	13	1775
Ovarian Cancer	9	490
Metastatic Breast Cancer and Colorectal Cancer	4	167
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer	4	170
Solid Tumor, Advanced solid malignancies	3	68
Advanced Ovarian Cancer or Metastatic Breast Cancer	2	144
Pancreatic or Ovarian Cancer	2	110
Chronic Refractory Immune (Idiopathic) Thrombocytopenic Purpura	2	32
Iron Deficiency Anemia	2	150
Rheumatoid Arthritis / Psoriasis, Knee Osteoarthritis	2	86
Acute Myeloid Leukemia in Remission Phase	1	60
Chronic Myeloid Leukemia	1	26
Malignant Gliomas	1	14
Philadelphia chromosome positive Chronic Myeloid Leukemia	1	42
Glioblastoma Multiforme or Anaplastic Astrocytoma	1	40
Breast cancer or Colorectal Cancer	1	39
Moderate to Severe Atopic Dermatitis	1	72




**50**  
Studies

**480**  
Sites

**3485**  
Patients

## Over 200 transdermal patch studies

- PK, Adhesion, and Irritation/Sensitization
- ANDA and NDA applications
- Strong training and validation program
- Complex statistical analysis
- All pivotal studies include cross-rater and cross-site validation as part of the study and reporting



# Nasal/Inhalation Experience

- **Negative Pressure Dosing Chamber in Las Vegas clinic:** Specifically designed to prevent cross-contamination on MDI, DPI, and Nasal Spray Studies.
  - Minimizes the potential for small air-borne drug particle cross-contamination.
  - All PK samples are collected/subjects are housed in separate areas from dosing and sample processing.
  - All PK samples are processed in a separate lab away from subjects and the dosing chamber.
- **Experience** in evaluating prototype (novel) actuators and prototype breath actuators.
- **SOPs** developed specifically for Orally Inhaled and Nasal Spray studies to help prevent cross-contamination of airborne particles.
- **Respiratory therapist** on-site for screening and dosing, upon request.
- **Complex statistical analysis** for in vitro population BE studies.



# Global Site Network | Investigator Sites





# **Labs** - Central Clinical Lab, Bioanalytical & Biosimilars

*Experience Laboratory Excellence with Lambda – Where Precision Meets Innovation*

## Comprehensive Services for all phases of Clinical Trial Testing

- Biomarkers
- Assay Development
- Safety Testing
- Hematology
- Cytology
- Biochemistry
- Immunology & Serology
- Molecular Biology
- Microbiology
- Coagulation study

Over **25** validated  
**Biomarkers**

Validated **LIMS**  
System

**Pan-India** capabilities for  
seamless **Sample Logistics**

**Microbiological testing** for  
Healthcare **Hygiene products**




## 1400+ Validated Bioanalytical Assays

- **GLP Certified** Lab with **Automated** Sample Inventory Management System and Liquid Handling System.
- Capacity to analyze **1,10,000+ Samples** per month.
- Specializing in method development, method validation and study sample analysis of complex molecules.
- Expertise in NCE molecules having quick turnaround time and pre-clinical studies having extremely low matrix volume.
- Expertise in molecules like Colesevelam, Sucralfate, and others requiring in-vitro studies for Bioequivalence.
- Fat estimation in fecal and food samples using FT-IR platform.
- TAT < 10 days for 8000+ samples in support of 505(b)(2)/F2F studies dossier filings.



## Extensive experience in MD/MV for generic, complex & NCE molecules


- Ultra-trace detection assay
- Endogenous assay
- Protein-bound & unbound assay
- Conjugated & unconjugated assay
- Liposomal-encapsulated & un-encapsulated assay
- Vitamin product assay
- Fat analysis in food and feces
- Light-sensitive assay
- Chiral assay
- Hormonal product assay
- Assay for highly unstable molecules
- Biphosphonate assay



	LC-MS/MS	FTIR	LHS	ICP-MS
Lambda	39	03	04	01
Novum	14	-	-	-

8-10 New method development per month

# Biosimilars & Large Molecule Analysis



## Ligand Binding Assay (ELISA, ECLIA)

- Pharmacokinetics Assay
- Immunogenicity Assay
- Biomarkers Assay
- Enzyme Assay
- In-vitro diagnostics Assay (IVD)

## Cell-Based Assay

- Neutralizing assay
- Cell Proliferation assay
- Cell signaling assay
- Flow Cytometry

## LC-MS/MS

- Pharmacokinetics Methods
- Biomarkers Methods
- Tissue distribution studies Methods


## ICP-MS

- Pharmacokinetics Methods
- Biomarkers Methods
- Elemental drug Analysis Methods

# Biosimilars & Large Molecule Services



Molecule	Methods
Denosumab	PK Immunogenicity (ADA and NAb), Biomarkers (P1NP, CTx, NTx)
Pertuzumab	PK, Immunogenicity (ADA and NAb)
Vedolizumab	Immunogenicity (ADA)
Trastuzumab emtansine (T-DM1)	Immunogenicity (ADA)
Trastuzumab (IV and SC)	PK, Immunogenicity (ADA and NAb)
Ranibizumab	PK, Immunogenicity (ADA and NAb)
Pegfilgrastim	PK, Biomarkers (ANC), Immunogenicity(ADA and NAb)
Teriparatide	PK, Biomarkers (serum Calcium), Immunogenicity (ADA and NAb)
Filgrastim	PK, Biomarkers (CD34+), Immunogenicity (ADA and NAb)
Bevacizumab	PK, Immunogenicity (ADA and NAb)
r-hFSH	PK, Biomarkers ( $\beta$ – Estradiol), Immunogenicity (ADA)
Adalimumab	PK, Immunogenicity (ADA and NAb)
Romiplostim	PK, Immunogenicity (ADA)
Enoxaparin	Biomarkers (Anti Factor Xa, Anti Factor IIa, TFPI)
Rituximab	PK, Biomarkers (CD 19), Immunogenicity (ADA)

A high-angle, blue-tinted photograph of two medical professionals in white lab coats sitting at a desk. They are looking at two large computer monitors. The left monitor displays a chest X-ray with patient information: 'Mc Brown L', '02-02-1957 M', 'LMO 1', 'CRA 1', and 'SD 102'. The right monitor shows a skull X-ray with a hand pointing at it; technical details include 'XQ2500VC', '4 Acc', '0', and 'img Tm: 18:25:5'. A tablet in the center of the desk also shows a skull X-ray. The desk has two keyboards, a mouse, and a small bowl of pills. The overall scene is dimly lit with a strong blue color cast.

# Medical Imaging

*Centralized imaging services to provide high quality data to support key clinical endpoints*

- Panel of Board-certified Radiologists
- Centralized Reading and Reporting
- Automated & paperless processes.
- 21 CFR Part 11 Compliant Digital Solutions
- Specializes in a wide range of imaging modalities:  
**OCT, FA, CFP, DXA, CT, PET scan, MRI**
- **DiSoft (Diagnostic Imaging Software)**, a customized web-based global imaging application, which enables the secure uploading, analysis, and storage of images for the evaluation of clinical trial endpoints.

Worked with **600+ clinical sites** for imaging,  
**5000+ Images** Reviewed

## Extensive Capabilities:



**Oncology**



**Musculoskeletal**



**Ophthalmology**

## Future Expansion Planning:

- iRECIST evaluation method
- Gastrointestinal (GI) imaging
- PCWG3 evaluation method

The background features a large, semi-transparent clock face with a hand pointing at it. Overlaid on this are several circular icons connected by a network of lines. The icons include: a brain with a Wi-Fi signal, a computer monitor with a double-headed arrow, three interlocking gears, a microchip with a checkmark, a bar chart with an upward arrow, and a circular flow diagram with arrows.

# Biostatistics & Data Management

*Ensuring High Data Quality, Integrity & Accurate Results*

- End-to-end Data Management services
- Quick & expandable DM resource model
- 21 CFR compliant in-house EDC systems
- CDASH (SEND) & CDISC (SDTM & ADaM) standards
- Visual Data Analytics
- Study design, sample size estimation
- Randomisation Generation & Management
- SAP, TLFs, SAR development
- PK/PD & Immunogenicity Data Analysis
- Population PK modelling & reporting

## Close-knit team of Data Managers, Programmers and Biostatisticians



A hand holding several white, oval-shaped pills. A large, semi-transparent checkmark icon is overlaid on the hand. The background is a blurred pharmacy shelf with various bottles and boxes, all tinted in a light blue color. A network of white dots and lines is overlaid on the scene, suggesting a digital or data-driven environment.

# Clinical Safety & Pharmacovigilance

*Empowering drug safety through end-to-end pharmacovigilance services*

# Clinical Safety & Pharmacovigilance

Experience & expertise in major Therapeutic Areas & Products

● **Drugs**


● **Medical Devices**

● **Combination Products**

● **Vaccines**

● **Biologics & Biosimilars**

● **Advanced therapy medicinal products**



## Operational Services

- ICSR Case Processing & Electronic Submissions of ICSRs
- Aggregate Reports (ARs) & Risk Management Plan (RMP / REMS)
- Literature Monitoring
- Signal Detection, Evaluation, & Management
- xEVMPD Compliance Solution & Services

## PV Systems

- QPPV Services in UK & EU
- LRPVs across Europe
- Global Safety Database (PvEDGE)
- Smart EV Triage Solution (PvDcode)

## Support Services

- PV consulting & Training
- PV Gap Analysis
- Quality Management System
- Global Compliance Monitoring
- Audits and Inspections Management

## Year 2023 at a Glance

**571,586**

Literature Screening

**89669**

Cases

**747**

Aggregate Reports

**165**

RMP

**1470**

Signal Management Reports






# Medical & Scientific Writing

*Fully-integrated Solutions with expertise in diverse therapeutic areas.*

## Support for Diverse Document Types:

- **Clinical Study Protocols**
- **Clinical Study Reports (CSR)**
- **Investigator's Brochure (IB)**
- **Regulatory Documents**
- **Drug Safety & Risk Management**
  - Aggregate reports (DSUR/PBRER/PSUR/PADER/SUSAR LL)
  - Risk management plans (EU/Core)

Expertise in **eCTD** submissions package for **USFDA, EMA, DCGI, TGA, ANVISA, HC** etc.




A hand is shown holding a glowing digital interface. The interface consists of a central circular node with a circular arrow icon, from which numerous lines radiate outwards to various icons representing different technologies and data concepts. These icons include a document, a bar chart, a magnifying glass, a location pin, a double-headed arrow, a laptop, a gear, a server rack, a monitor, a Wi-Fi symbol, a globe, a cloud, a microchip, a signal tower, a bar chart with a line, a document with a checkmark, and a gear with a plus sign. The background is a blurred image of a person's hand holding a smartphone, overlaid with a blue tint and a network of white lines and icons.

# Technologies

*Innovating for Clinical Excellence*

# Digital Infrastructure & Automation



- Clinical Trial Management System (CTMS)
  - Protocol Deviation Management System (PDMS)
  - Interactive Web Response System (IWRS)
  - Clinical Trial Supply Management (IMPTrack-WHS)
  - Medical Imaging Software (Di-Soft)
  - Electronic IRB (EC Approval)
  - Sample Information Management System (SIMS)
  - EDC - BizNet, Medidata, TrialMaster
  - Electronic Lab Notebook platform (ELN)
  - Comprehensive Bioanalytical Solutions (BioLyte)
  - Laboratory Information Management System (LIMS)
  - Pharmacy Supply Management (IMPTrack)
  - PV & Drug Safety Database (PvEdge)
  - Medical Information Management (PrITR)
- eTMF
  - Realtime Monitoring Dashboards
  - SAS
  - Phoenix WinNonlin
- Quality Management System (QMS)
  - Training Management System (TMS)
  - Secure eSignature Solution (DocStack)
  - Document Management System
  - HRMS - SAP SuccessFactors
  - Data Archival Solution (StackTrack)
- Multi-factor authentication (MFA)
  - Vulnerability Assessment & Penetration Testing
  - Extended Detection and Response (XDR)
  - Backups/Disaster Recovery
  - Firewalls
  - Encryptions
  - Secured VPNs



## Services

- Global Footprint
- World-class Infrastructure
- One-stop solution for your drug development journey
- Hub & Spoke, flexible business model
- Strong financials offering stability and flexibility for upscaling



## Experience

- Team of Industry-leading domain experts
- Experience in conducting 7500+ PK studies
- 265+ multicentric studies
- Flexible, amiable, and adaptable culture fostered by 1200+ Professionals



## Quality

- Proven Regulatory Track Record
- QMS-backed Strong Governance Structure
- “Quality by Design”-driven decision making
- GDPR Compliance
- Transparency at each step



Let's Connect

✉ [BD@lambda-cro.com](mailto:BD@lambda-cro.com)